NIH-funded study identifies gene variant as potential drug target
Defying the odds, an individual at high risk for early-onset Alzheimer’s disease remained dementia-free for many years beyond what was anticipated. A study funded in part by the National Institute on Aging (NIA), part of the National Institutes of Health, led researchers to suggest that a gene variant may be the key, perhaps providing a new direction toward developing a treatment.
The research focused on the case of a woman who carried a gene mutation known to cause early-onset Alzheimer’s. However, she did not develop signs of the disease until her seventies, nearly three decades after her expected age of onset. The researchers suspect that she may have been protected because in addition to the gene mutation causing early-onset Alzheimer’s in her family, she also had two copies of the APOE3 Christchurch (APOE3ch) gene variant. Findings of this case study as published in Nature Medicine suggest that two copies of the APOE3ch variant, named after Christchurch, New Zealand where it was first identified, may protect against Alzheimer’s.
“Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field,” said NIA Director Richard J. Hodes, M.D. “We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information.”
Early-onset Alzheimer’s disease is rare, representing less than 10% of all people who have Alzheimer’s. It typically occurs between a person’s 30s to mid-60s. Risk for both early- and late-onset Alzheimer’s disease is affected by genetic factors.
For the study, researchers led by investigators at Massachusetts General Hospital, Boston, in collaboration with the University of Antioquia, Medellin, Colombia, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, and Banner Alzheimer’s Institute, Phoenix, looked at genetic data from a Colombian family with more than 6,000 living members. Family members who carry a rare gene mutation called Presenilin 1 (PSEN1) E280A, have a 99.9% risk of developing early-onset Alzheimer’s disease.
The researchers confirmed that the woman in this case carried the PSEN1 E280A mutation, which caused early-onset Alzheimer’s in her other family members. However, she also had two copies of the APOE3ch gene variant, while no other affected family member carried two copies of this variant. Affected family members develop Alzheimer’s in their 40s, but she remained disease free until her 70s. Imaging tests showed that the woman had only minor neurodegeneration. She did have large amounts of amyloid protein deposits, a hallmark of Alzheimer’s disease, in her brain. But the amount of tau tangles, another hallmark of the disease, and the one more correlated with how thinking and memory are affected, was relatively low.
Experiments as part of the study showed that the APOE3ch variant may reduce the ability of APOE to bind to certain sugars called heparan sulphate proteoglycans (HSPG). APOE binding to HSPG has been implicated as one mechanism that may contribute to the amyloid and tau protein deposits that destroy the brain. The research suggests that a drug or gene therapy that could reduce APOE and HSPG binding has the potential to be a new way to treat or prevent Alzheimer’s disease.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Biogen's stock could fall 10% on new Alzheimer's drug data this week, top analyst sayson December 2, 2019 at 12:56 pm
Biogen's stock could fall as much as 10% once it releases new data this week on its Alzheimer's drug, analyst Brian Skorney says. "We do not think that data validates anything near receiving approval ...
- C 2 N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathologyon December 2, 2019 at 12:51 pm
Dr. Tim West Ph.D. to Present at CTAD 2019 in Late-Breaking Oral Session ST. LOUIS--(BUSINESS WIRE)--C 2 N Diagnostics today announced that it will present data from a proof-of-concept study of its ...
- Only ‘GOOP subscribers’ would buy data for Biogen Alzheimer’s drug, analyst writes in scathing noteon December 2, 2019 at 12:47 pm
A biotechnology company’s plans to file for Food and Drug Administration approval of a drug to treat Alzheimer’s disease despite ending its clinical trial program following a futility analysis have ...
- Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgradeon December 2, 2019 at 10:55 am
Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis. Ahead of ...
- New drug shows promising results in the treatment of Alzheimer’son December 2, 2019 at 10:19 am
OMAHA, Neb. (WOWT/Gray News) - Alzheimer’s disease affects some 5 million people in the United States, and as the population ages, doctors estimate those affected will more than double by 2050. A new ...
- Biogen's shares drop on critical view of Alzheimer's dataon December 2, 2019 at 9:56 am
Biogen BIIB, -2.56% shares fell 2.6% after an analyst scoffed at the possibility of a Food and Drug Administration approval for the company's experimental Alzheimer's disease treatment. "There are so ...
- Predicting Alzheimer's-like memory loss before it strikeson December 2, 2019 at 8:38 am
For someone with Alzheimer's disease, there's no turning back the clock. By the time memory loss and other worrisome signs appear, cognitive decline has already begun. "Being able to predict deficits ...
- Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Sayson December 2, 2019 at 7:31 am
On Monday morning, he stuck it into Biogen. In a scathing note, Skorney laid out the case that Biogen’s experimental Alzheimer’s drug aducanumab won’t get approved by the Food and Drug Administration.
- CorTechs Labs Presents Findings Regarding Alzheimer’s Disease at the Radiological Society of North America’s (RSNA) 2019 Annual Meetingon December 2, 2019 at 7:05 am
In addition to technical exhibits on both the main floor and AI Showcase, the company will present their findings from a recent study titled: “Determining Brain Age Using Machine Learning Combined ...
- Grifols to present latest Alzheimer's clinical trial resultson December 2, 2019 at 6:28 am
BARCELONA, Spain, Dec. 2, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, ...
via Bing News